Internal and Emergency Medicine

, Volume 3, Issue 1, pp 53–56

Rimonabant for overweight and “metabolic syndrome”: the attempt to supersize disease and risk by pharmaceutical marketing

  • Rita Banzi
  • Lorenzo Moja
  • Ivan Moschetti
  • Alessandro Liberati
  • Gian Franco Gensini
  • Roberto Gusinu
  • Andrea A. Conti
CE - Cochrane's Corner

DOI: 10.1007/s11739-008-0139-x

Cite this article as:
Banzi, R., Moja, L., Moschetti, I. et al. Intern Emerg Med (2008) 3: 53. doi:10.1007/s11739-008-0139-x
  • 60 Views

Copyright information

© SIMI 2008

Authors and Affiliations

  • Rita Banzi
    • 1
  • Lorenzo Moja
    • 1
  • Ivan Moschetti
    • 1
  • Alessandro Liberati
    • 1
  • Gian Franco Gensini
    • 2
  • Roberto Gusinu
    • 3
  • Andrea A. Conti
    • 4
  1. 1.Italian Cochrane CentreMario Negri Institute for Pharmacological ResearchMilanItaly
  2. 2.Department of Critical Care Medicine and SurgeryUniversity of Florence and Azienda Ospedaliero-Universitaria CareggiFlorenceItaly
  3. 3.DAI Cardiologico e dei Vasi, Azienda Ospedaliero-Universitaria CareggiFlorenceItaly
  4. 4.Department of Critical Care Medicine and SurgeryUniversity of Florence and Don Carlo Gnocchi Foundation IRCCSFlorenceItaly